EGFR and head and neck squamous cell carcinoma: However, Rampias and his colleagues [15] suggested that Harvey rat sarcoma viral oncoprotein (HRAS) mutations could mediate cetuximab resistance in systemic therapy of HNSCC via the EGFR/rat sarcoma (RAS)/extracellular signal-regulated kinases (ERK) signaling pathway.